Diabetes, Glycemic Control, and New-Onset Heart Failure in Patients With Stable Coronary Artery Disease: Data from the Heart and Soul Study by van Melle, Joost P. et al.
Diabetes, Glycemic Control, and New-
Onset Heart Failure in Patients With Stable
Coronary Artery Disease
Data from the Heart and Soul Study
JOOST P. VAN MELLE, MD, PHD
1
MARISKA BOT, MSC
2
PETER DE JONGE, PHD
2,3
RUDOLF A. DE BOER, MD, PHD
1
DIRK J. VAN VELDHUISEN, MD, PHD
1
MARY A. WHOOLEY, MD, PHD
4
OBJECTIVE — Diabetes is a predictor of both coronary artery disease (CAD) and heart
failure. It is unknown to what extent the association between diabetes and heart failure is
inﬂuenced by other risk factors for heart failure.
RESEARCHDESIGNANDMETHODS — Weevaluatedtheassociationofdiabetesand
A1C with incident heart failure in outpatients with stable CAD and no history of heart failure
(average follow-up 4.1 years).
RESULTS — Of 839 participants, 200 had diabetes (23.8%). Compared with patients who
didnothavediabetes,thosewithdiabeteshadanincreasedriskofheartfailure(hazardratio[HR]
2.17[95%CI1.37–3.44]).AdjustmentforriskfactorsforCAD(age,sex,race,smoking,physical
inactivity, obesity, blood pressure, and LDL cholesterol), interim myocardial infarction, and
myocardial ischemia did not alter the strength of the association between diabetes and heart
failure.Afterinclusionalsoofotherriskfactorsforheartfailure(leftventricularejectionfraction,
diastolic dysfunction, and C-reactive protein) and medication use, diabetes remained an inde-
pendent predictor of heart failure (HR 3.34 [95% CI 1.65–6.76]; P  0.001). Each 1% increase
in A1C concentration was associated with a 36% increased HR of heart failure hospitalization
(HR 1.36 [95% CI 1.17–1.58]).
CONCLUSIONS — In patients with stable CAD who are free from heart failure at baseline,
diabetes and glycemic control are independent risk factors for new-onset heart failure. The
mechanisms by which diabetes and hyperglycemia lead to heart failure deserve further study, as
the association is independent of baseline functional assessment of ischemia, systolic and dia-
stolic function, and interim myocardial infarction.
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H
eart failure is an enormous burden
of disease, leading to substantial
health care costs. Despite advances
in treatment, the number of heart failure
hospitalizations has increased steadily.
The 2005 Heart Failure Guidelines of the
American College of Cardiology/
American Heart Association (1) and Eu-
ropean Society of Cardiology (2)
emphasized the importance of identiﬁca-
tion and treatment of risk factors. Among
the patients classiﬁed in the highest risk
grouparepatientswithdiabetes.Diabetes
is associated with incident heart failure in
the general population (3,4) and with ad-
verse outcomes among patients with al-
ready existing heart failure (5). Diabetes
also predicts heart failure in patients with
acute coronary syndromes (6). Whether
diabetes predicts heart failure in patients
with stable coronary artery disease (CAD)
has not been evaluated in detail.
The precise underlying mechanism
by which diabetes portends heart failure
is unclear. In fact, it remains to be eluci-
dated whether in this context the diagno-
sis of diabetes per se is more important
than just the presence of inadequate gly-
cemic control. CAD is the number one
risk factor for heart failure in the devel-
oped world (1,2). Because diabetes is
strongly associated with CAD, it is plau-
sible to attribute the risk of heart failure
associated with diabetes to the effects of
CAD. However, although it is known that
hyperglycemia predicts heart failure
among diabetic patients with CAD (7), it
isnotknownwhetherthisriskisindepen-
dent of CAD severity, CAD progression,
or the presence of myocardial ischemia.
EvenintheabsenceofCAD,patientswith
diabetesshowchangesinmyocardialper-
formance that put them at risk for heart
failure (diabetic cardiomyopathy).
Todeterminetowhatextenttheasso-
ciation between diabetes and heart failure
isinﬂuencedbyotherriskfactorsforheart
failure (including interim myocardial in-
farctionandthepresenceofbaselinemyo-
cardialischemia),weevaluatedtheriskof
heart failure associated with diabetes in a
cohort of outpatients with stable CAD.
The cohort is derived from the Heart and
SoulStudy(8),whichallowsthoroughin-
vestigation of the strength of the associa-
tion between diabetes (both the diagnosis
per se and the level of glycemic control)
and future heart failure episodes, while
taking into account the above-mentioned
established and presumed risk factors.
RESEARCH DESIGN AND
METHODS— The Heart and Soul
Studyisaprospectivecohortstudyofpsy-
chosocial factors and health outcomes in
patients with stable CAD. Design of the
study has been published previously (8).
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outpatient clinics of 12 different centers
in the San Francisco Bay area if they met
one or more of the following inclusion
criteria: prior myocardial infarction, an-
giographic evidence of 50% stenosis in
one of the coronary arteries, prior coro-
nary revascularization, and exercise-
induced ischemia (treadmill or nuclear
scintigraphy). Exclusion criteria were
acute coronary syndrome within the past
6 months, the inability to walk one block,
andplanstomoveoutoftheareawithin3
years.
Between September 2000 and De-
cember 2002, 1,024 patients were en-
rolled in the study. For the current
investigation, 185 patients (18.1%) were
excluded because they had a history of
heart failure (n  179) or heart failure
status was unknown (n  6).
Baseline study variables
All patients completed a daylong baseline
studyvisitthatincludedamedicalhistory
interview, physical examination, ques-
tionnaire, laboratory analysis, exercise
test, and echocardiogram. Diabetes was
deﬁned as self-reported diabetes or the
use of antidiabetes medication. Alcohol
use was determined by questionnaire.
Participants rated their physical activity
during the previous month using a
6-point Likert scale. Those responding
“not at all active” or “a little active” were
classiﬁed as physically inactive. An esti-
mateofchronicglycemiawasprovidedby
serum A1C measurement. Serum glucose
level, A1C, LDL cholesterol, and C-reac-
tive protein (CRP) were assessed by stan-
dard routine biochemistry analysis after
an overnight fast (except for taking their
regularly prescribed medication with wa-
ter) using a venous blood sample, drawn
via a 21-gauge butterﬂy needle. Subjects
were considered to have metabolic syn-
drome if they met the criteria of the Na-
tional Cholesterol Education Program
(9). Echocardiography was performed
with an Acuson Sequoia Ultrasound Sys-
tem (Siemens Medical Solutions USA,
Malvern, PA), with a 3.5-MHz trans-
ducer. Left ventricular ejection fraction
(LVEF)wascalculatedusingthemodiﬁed
Simpson rule as recommended by the
American Society of Echocardiography
(10). In addition, a full description of di-
astolic function was performed according
to predeﬁned established criteria (nor-
mal, impaired, pseudonormal, or restric-
tive diastolic function). An exercise
treadmill test (standard Bruce protocol)
was performed. Immediately after exer-
cise, echocardiographic analysis was per-
formed to investigate exercise-induced
wall motion abnormalities, which served
as an indicator of myocardial ischemia
(11).Detailspertainingtoacquisitionand
analyses of echocardiographic data were
reportedelsewhere(12).Theinstitutional
reviewboardateachofthesitesapproved
the study protocol, and all participants
provided written informed consent.
End points
Themainstudyoutcomewastimetohos-
pitalization for heart failure, as was previ-
ously reported for the whole cohort in
detail (13). Heart failure was diagnosed
according to established criteria (1,2) us-
ing clinical and radiological evaluation.
Potential events were recorded annually
by telephonic interviews. Additional in-
formation (e.g., medical records and
death certiﬁcates) was collected and re-
viewed by two independent and blinded
adjudicators. Discrepancies were dis-
cussed, and decisions were made by una-
nimity. In case of disagreement, a third
blinded adjudicator was consulted. Fol-
low-up was completed for all patients.
Statistical analysis
The study sample comprised 839 pa-
tients. Baseline differences between par-
ticipants with diabetes and without were
compared using t tests for continuous
variables and 
2 tests for dichotomous
variables.
In addition to the association of dia-
betes per se with hospitalization for heart
failure, we investigated the role of glyce-
mic control in the development of heart
failure. A1C was used as a proxy measure
for glycemic control (both dichotomized
and continuous, per 1% change). For the
former categorization, a cutoff of 6.5%
and 6.5% was used because this cutoff
was recently used to redeﬁne the diagno-
sis of diabetes (14). The following analy-
ses were conducted with diabetes and
A1C as independent variables.
First, Kaplan-Meier analysis was used
toestimatethetimefrombaselinetoheart
failure hospitalization in patients with or
without diabetes and in patients with low
or high A1C. The log-rank test was used
for bivariate signiﬁcance testing. In addi-
tion, given the inﬂuence of antidiabetes
medication on A1C levels, we compared
the effect of glycohemoglobin on heart
failure in patients taking antidiabetes
medication.
Second, Cox proportional hazard re-
gression analyses were performed to in-
vestigate the impact of diabetes and A1C
level,respectively,onthetimetoﬁrsthos-
pitalization for heart failure. To study the
impact of diabetes and A1C on heart fail-
ureinthecontextofseveralpotentialcon-
founders,wemadeaselectionofthemost
important risk factors for heart failure
basedonrecentguidelines(1,2).Wethen
applied the following series of a priori de-
terminedCoxregressionmodelsinwhich
we sequentially controlled for the follow-
ing groups of confounders: model 1: age,
sex, and race; model 2: smoking, physical
inactivity, BMI, LDL cholesterol, and sys-
tolicbloodpressure;model3:myocardial
infarction during follow-up; model 4:
LVEF; model 5: exercise-induced wall
motion abnormalities (i.e., ischemia);
model 6: diastolic dysfunction; model 7:
logCRP; and model 8: ACE inhibitor/
angiotensin receptor blocker (ARB) and
-blocker-use. All models included age,
sex,andrace.Intheﬁnalmodel(model9)
weincludeallthevariablesthatwereused
inmodels1–8.Finally,insensitivityanal-
yses, the relationship between several
other deﬁnitions of diabetes and time to
onset of heart failure were tested. These
deﬁnitions were 1) self-reported diagno-
sisofdiabetes(irrespectiveofantidiabetes
medication use), 2) fasting blood glucose
126mg/dl,and3)fastingbloodglucose
126 mg/dl or use of antidiabetes medi-
cation. Moreover, the presence of meta-
bolic syndrome was tested in sensitivity
analyses.P0.05wasusedforallteststo
indicate statistical signiﬁcance. Hazard
ratios (HRs) with 95% CIs are reported.
Allstatisticalanalyseswereperformedus-
ing SPSS (version 17.0 for Windows;
SPSS, Chicago, IL).
RESULTS— Baselinecharacteristicsof
the study population (n  839) are out-
lined in Table 1. Mean age was 67 years,
and 200 patients (23.8%) had diabetes.
Diabetes as a predictor of heart
failure hospitalizations
During a mean  SD follow-up of 4.1 
1.2 years, 30 (15.0%) patients with dia-
betes and 47 (7.4%) patients without di-
abetes developed heart failure. Between
baseline and end of follow-up (either
heart failure event or end of study), 52
patients (6.2%) had a myocardial infarc-
tion. In Fig. 1, Kaplan-Meier analysis
shows the proportion of patients with
hospitalizations for heart failure divided
into patients with and without diabetes.
In Table 2, results of the Cox regression
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niﬁcantpredictorofheartfailurehospital-
ization (HR 2.17 [95% CI 1.37–3.44];
P  0.001). Diabetes remained a strong
predictor of heart failure while adjust-
ments were made for other predeﬁned
predictors of heart failure. Thus, adjust-
ment for age, sex, race, smoking, physical
inactivity, BMI, LDL cholesterol, systolic
blood pressure, myocardial infarction
during follow-up, LVEF, exercise-
induced wall motion abnormalities (i.e.,
ischemia), diastolic dysfunction, or CRP
did not attenuate the strength of the rela-
tionship between diabetes and heart fail-
ure. In the fully adjusted model, diabetes
was associated with an increased HR for
hospitalization because of heart failure
(3.34[1.65–6.76];P0.001).Othersig-
niﬁcant multivariable predictors were age
(years, HR 1.06), smoking status (3.01),
physical inactivity (2.18), LVEF (percent,
0.94), exercise-induced wall motion ab-
normalities (2.34), diastolic dysfunction
(1.26–4.97, depending on the grade of
diastolic dysfunction), and logCRP
(2.10).
Glycemic control
Diabetes was correlated with the level of
A1C (correlation coefﬁcient r  0.635,
P  0.001). Patients who were hospital-
ized for heart failure had signiﬁcantly
higher A1C levels than those who re-
mained free from hospitalization (6.4 
1.4 vs. 5.9  1.0%; P  0.003). Patients
who developed heart failure had border-
linesigniﬁcantlymoreoftenahighlevelof
A1C (6.5%), compared with patients
who remained free of heart failure (24.7
vs. 16.6%; P  0.07). In Fig. 2, Kaplan-
Meier analysis shows the proportion of
patientswithhospitalizationforheartfail-
ure divided into patients with high and
low A1C levels (log-rank test P  0.07).
Subgroup analysis revealed that, in pa-
tients who used antidiabetes medications
(n  156), the level of A1C was not re-
lated to new-onset heart failure (P 
0.21).
In Cox regression analysis,
A1C6.5% was borderline signiﬁcantly
related to incidence of new onset of heart
failure (HR 1.61 [95% CI 0.96–2.71];
P  0.07) (Table 2). With adjustment for
the predeﬁned predictors, on average,
A1C remained a borderline signiﬁcant
predictor for heart failure.
When A1C was entered into Cox re-
gressionanalysisasacontinuousvariable,
A1C was strongly related to heart failure
outcome. Each percent increase in A1C
was associated with a HR of 1.36 ([95%
CI 1.17–1.58]; P  0.001) for the inci-
dence of heart failure hospitalization.
Model-like adjustments did not decrease
HRssigniﬁcantly(Table2).Asshownalso
in Table 2, diabetes was associated with a
higherHRforheartfailurehospitalization
than A1C (dichotomized with a cutoff of
6.5%).
Figure 1—Proportions of patients free of hospitalization for heart failure divided into patients
with diabetes (     ) and patients without diabetes (——).
Table 1—Baseline characteristics
No diabetes Diabetes P value
n 639 200
Age (years) 67.4  11.0 65.3  10.3 0.02
Sex, male (%) 528 (82.6) 161 (80.5) 0.49
Race, white (%) 416 (65.2) 88 (44.0) 0.001
BMI (kg/m
2) 27.9  4.7 29.9  6.0 0.001
Smoking (%) 124 (19.4) 34 (17.0) 0.44
Heavy alcohol use (%) 215 (33.8) 38 (19.0) 0.001
Physical inactivity (%) 221 (33.1) 85 (42.5) 0.02
LDL cholesterol (mg/dl) 106 (34) 100 (32) 0.03
A1C (%) 5.5  0.5 7.1  1.4 0.001
Systolic blood pressure (mmHg) 132  20 137  23 0.003
Medical history
Myocardial infarction (%) 313 (49.1) 106 (53.8) 0.25
Revascularization (%) 367 (57.4) 104 (52.3) 0.20
Medication use
ACE inhibitor/ARB (%) 261 (40.8) 136 (68.0) 0.001
-Blocker (%) 343 (53.7) 129 (64.5) 0.007
Baseline LVEF (%) 62.7  8.6 63.1  8.8 0.59
Diastolic function (%) 0.22
Normal 361 (63.2) 116 (63.7)
Impaired 151 (26.4) 40 (22.0)
Pseudo/restricted 59 (10.3) 26 (14.3)
Exercise-induced wall motion abnormalities (%) 128 (21.5) 44 (24.4) 0.40
Creatinine clearance (ml/min) 82.4  26.9 82.0  31.2 0.87
CRP (mg/l) 4.0  6.8 4.8  7.0 0.11
Data are means  SD unless otherwise indicated. CRP was log-transformed for statistical analysis.
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Sensitivity analyses using different diabe-
tes deﬁnitions showed similar statistically
signiﬁcantoutcomeswithrespecttoheart
failuredevelopment(datanotshown).All
HRs were between 1.95 and 2.23 for uni-
variable analyses and 1.87 and 3.81 for
multivariable analyses. Metabolic syn-
drome was not signiﬁcantly related to
heart failure in unadjusted analyses (HR
1.40 [95% CI 0.89–2.19]; P  0.143).
However, after adjustment for age and sex,
metabolic syndrome was borderline statis-
tically signiﬁcant related to heart failure
(1.56 [95% CI 0.99–2.45]; P  0.054).
CONCLUSIONS— In the present
study, we established that diabetes and
glycemic control are independent risk
factors for the development of heart fail-
ure in patients with stable CAD.
Diabetes as a risk factor for heart
failure
The ﬁrst observation that diabetes was
linked to the development of heart failure
wasdemonstrated30yearsago(15).Nev-
ertheless, only recently has heart failure
beenacknowledgedasaseriousandoften
fatalcomplicationforpatientswithdiabe-
tes (16). Other studies (3,17) reported
that, in the general population, diabetes
increasestheriskforheartfailureapprox-
imately twofold. Studies in elderly indi-
viduals (18), patients with high-risk
vascular disease (19), patients with myo-
cardial infarctions (6) or patients with
chronicheartfailure(20)hadcomparable
observations, although some of them
failed to adjust for accepted confounding
factors such as diastolic dysfunction
(6,18–20) or LVEF (19). Our data extend
this knowledge as we performed several
important assessments.
First, we assessed the strength of the
association between diabetes and heart
failure in a population with stable CAD.
In this patient group, we found a more
than twofold elevated risk for heart fail-
ure, attributable to diabetes (HR 2.17).
This result is in line with recent outcomes
from a placebo-controlled ACE inhibitor
trial (21). The association persisted after
adjustment for age, sex, race, smoking,
physical inactivity, BMI, LDL cholesterol,
and systolic blood pressure. Because in-
terim myocardial infarction (as a surro-
gatemeasureforprogressionofCAD)and
exercise-induced wall motion abnormali-
ties also did not attenuate the strength of
the association between diabetes and
heart failure, our data suggest that diabe-
tes is a risk factor for heart failure, inde-
pendent of CAD risk factors, CAD
Figure 2—Proportions of patients free of hospitalization for heart failure divided into patients
with high A1C levels (6.5%;      ) and patients with low A1C levels (6.5%; ——).
Table 2—Diabetes and A1C as risk factors for heart failure hospitalization (multivariable Cox regression)
Diabetes as
predictor for
heart failure P value
A1C 6.5% as
predictor for
heart failure P value
A1C (%) as
predictor for
heart failure P value
n 839 832 832
Univariable analysis 2.17 (1.37–3.44) 0.001 1.61 (0.96–2.71) 0.071 1.36 (1.17–1.58) 0.001
Model 1 2.50 (1.57–4.01) 0.001 1.72 (1.02–2.92) 0.043 1.46 (1.24–1.73) 0.001
Model 2 2.65 (1.61–4.36) 0.001 1.58 (0.90–2.78) 0.114 1.50 (1.26–1.79) 0.001
Model 3 2.53 (1.58–4.07) 0.001 1.72 (1.02–2.92) 0.043 1.48 (1.25–1.76) 0.001
Model 4 2.79 (1.74–4.50) 0.001 2.03 (1.18–3.47) 0.010 1.46 (1.24–1.71) 0.001
Model 5 2.19 (1.29–3.71) 0.003 1.50 (0.82–2.73) 0.189 1.33 (1.09–1.61) 0.004
Model 6 2.60 (1.55–4.36) 0.001 2.02 (1.16–3.52) 0.014 1.48 (1.24–1.75) 0.001
Model 7 2.42 (1.50–3.90) 0.001 1.71 (1.01–2.92) 0.047 1.39 (1.17–1.64) 0.001
Model 8 2.49 (1.52–4.08) 0.001 1.67 (0.98–2.84) 0.061 1.45 (1.22–1.72) 0.001
Model 9 (full) 3.34 (1.65–6.76) 0.001 2.27 (1.06–4.87) 0.036 1.40 (1.13–1.74) 0.003
DataareHR(95%CI)unlessotherwiseindicated.Model1:age,sex,andrace.Model2:age,sex,race,smoking,BMI,physicalinactivity,LDLcholesterol,andsystolic
bloodpressure.Model3:age,sex,race,andmyocardialinfarctionduringfollow-up.Model4:age,sex,race,andLVEF.Model5:age,sex,race,andexercise-induced
wall motion abnormalities. Model 6: age, sex, race, and diastolic dysfunction. Model 7: age, sex, race, and logCRP. Model 8: age, sex, race, ACE inhibitor/ARB and
-blocker use. Model 9: age, sex, race, smoking, BMI, physical inactivity, LDL cholesterol, systolic blood pressure, myocardial infarction during follow-up, LVEF,
exercise-induced wall motion abnormalities, diastolic dysfunction, logCRP, and ACE inhibitor/ARB and -blocker use.
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myocardial ischemia.
Adequate adjustment is important
because diabetes is a disorder that fre-
quentlyisclusteredwithotherriskfactors
for CAD and heart failure. Without this
adjustment, an estimation of the real
strengthoftheassociationbetweendiabe-
tes and heart failure remains a subject of
discussion, making the causality issue a
matter of speculation. Yet, as far as we
know, no previous studies took into ac-
count the severity of the underlying car-
diac disease as extensively as we did
herein. This strategy conﬁrmed not only
thatdiabetesisanindependentriskfactor
for heart failure but it also showed also
that diabetes, compared with other es-
tablishedriskfactors(e.g.,age,smoking
status, physical inactivity, LVEF, exer-
cise-induced wall motion abnormali-
ties, diastolic dysfunction, and CRP), is
among the key players in heart failure
development.
Second, because diabetes emerged as
a risk factor for heart failure, we investi-
gated whether the level of glycemic con-
trol is related to the incidence of heart
failure hospitalizations. Previous studies
have been inconsistent on this point. Al-
though the majority of studies point to a
relation between glucose levels and heart
failure (4,19,22), a report of the Cardio-
vascular Health Study (18) showed no
association after adjustment for demo-
graphic data and baseline disease. Impor-
tantly, these studies measured glycemia
onasingleoccasion.However,thewidely
used clinical test, A1C, which reﬂects
mean blood glucose over the previous
8–12 weeks, may be more informative in
termsofapatient’sglucosecontrol.Inour
study, A1C was strongly associated with
newheartfailureepisodesasacontinuous
variable, whereas it was borderline signif-
icant as a dichotomized variable. This
ﬁnding is in line with a study by Nichols
et al. (23) and remained robust in analy-
ses incorporating other important covari-
ates of heart failure development. The HR
of heart failure hospitalization was larger
for diabetes than for A1C, suggesting that
the level of glycemic control may not be
the crucial factor when one is unraveling
causality between diabetes and heart fail-
ure. However, it should be emphasized
that this result was based on a single mea-
surement of A1C at baseline and did not
necessarily reﬂect glycemic control dur-
ing the follow-up period. Nevertheless,
this idea is supported by our observation
that in patients who used antidiabetes
medications (n  156), those with ade-
quate glucose control did not differ from
those with poorly regulated diabetes in
terms of heart failure outcome. Another
study(24)alsofailedtoﬁndarelationship
between effective antidiabetes treatment
(in terms of glycemic control) and im-
provement in heart failure outcome.
The reason that diabetes (or the lack
ofglycemiccontrol)isrelatedtoheartfail-
ure has been intensively investigated.
Both preclinical and clinical studies re-
sulted in the identiﬁcation of potential
pathways leading to “diabetic cardiomy-
opathy”(25,26):facilitationofatherogen-
esis, autonomic dysfunction, interstitial
ﬁbrosis, glycation of interstitial proteins,
impaired calcium homeostasis, upregula-
tion of the renin-angiotensin system, in-
creased oxidative stress, altered substrate
metabolism, and mitochondrial dysfunc-
tion. In our study, the strength of the as-
sociation between diabetes and heart
failure did not attenuate after adjustment
for established risk factors for heart fail-
ure, suggesting that traditional risk fac-
tors are not responsible for the
detrimental association, giving fuel to the
diabetic cardiomyopathy hypothesis.
Study limitations
Our results must be interpreted in the
light of several limitations. First, no cath-
eterization was performed at baseline to
ascertain the extent of CAD. However, we
think that in the context of the develop-
ment of heart failure, a functional assess-
ment (i.e., inducible myocardial
ischemia) is even more important. In our
study, a method with high accuracy was
used to detect myocardial ischemia (i.e.,
exercise-induced wall motion abnormali-
ties) (11). Second, because our study
populationconsistedonlyofpatientswith
stable CAD, conclusions cannot be ex-
trapolated to populations with unstable
coronary syndromes.
Insummary,ourstudyendorsesonce
more the detrimental inﬂuence of diabe-
tes on heart failure prognosis. In the con-
textofheartfailuredevelopment,thelevel
of A1C, as a measure of cumulative glyce-
mic burden, is an important marker of
increased risk. Because prevention of
heart failure is an important public health
goal and no clear improvement in event
rates was noted during the past few years,
future studies should focus on the mech-
anism by which diabetes leads to heart
failure and how these effects can be
prevented.
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